adagrasib
mirati
['nsclc', 'lung', 'lcsm,(-blcsm)', 'sclc', 'adagrasib']
treatment with the #kras g12c inhibitor #adagrasib showed a promising objective response rate and disease control rate in patients with previously treated kras g12c mutated non small cell lung cancer. #lcsm #nsclc #asco22 
Oncology news and insights from leading researchers and cancer centers.